Bridging the gap in your Phase I clinical studies. 

The pharmaceutical market in Japan holds the second-largest position globally. To meet the healthcare demands of its population, Japan heavily depends on the import of pharmaceutical products. In order to leverage these opportunities, drug developers must adhere to the rigorous regulations set by the Pharmaceuticals and Medical Devices Agency (PMDA).

Richmond Pharmacology possesses the necessary expertise to assist you in bridging the gap for your upcoming Phase I clinical study.

x

Learn about the bridging studies conducted at Richmond Pharmacology

A single centre study for Chiesi Pharmaceuticals. 16 Japanese and 16 Caucasian volunteers participated in cross over, bridging study for Chronic obstructive pulmonary disease. Read about our approach and the controls we introduced to reduce variability. Learn more here.

A cognitive function profile of a second generation antihistamine. The effect of rupatadine on cognitive functioning was evaluated by means of computerized cognitive tests: rapid visual information processing (RVP), reaction time (RT), spatial working memory (SWM) and visual analogue scales (VAS) with 27 Japanese volunteers. Learn more here.

Why Richmond Pharmacology

TAP OR CLICK A BLOCK BELOW TO LEARN MORE

Expertise in PMDA criteria

We have conducted more than 100 ethnic bridging studies enabling us to build a trusted relationship with the PMDA.

Read more +

20,000 active 1st generation Japanese subjects

Our recruitment database is the largest in Europe with more than 20,000 active 1st generation Japanese subjects. 

Read more +

Short- and long-term residency periods

We can accommodate studies with short-term and long-term residency periods.

Read more +

Richmond Pharmacology's ethnic bridging studies will reduce the PMDA approval timeline and accelerate your time to market.

Fast track your global marketing approvals

Our expertise can help you accelerate your drug development timelines globally

Get in touch today

Latest news

Characterisation of the Cardiovascular Effects of a Meal: QTcF Assessment and Further Insights into the Physiological Effects

December 4, 2023
Groundbreaking research paper authored by Dr. Georg Ferber, Dr. Dilshat Djumanov, Dr. Ulrike Lorch, Dr. Edward Jackson, Dr. Joao Almeida Melo, Mr. James Rickard, and Dr. Jorg Taubel. 
Read more

Richmond Pharmacology becomes Richmond in Brand Refresh

December 1, 2023
Refreshed brand reflects company’s growth over 22 years and renewed commitment to turning hope into reality for patients.
Read more

Events

The 44th Annual Scientific Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT)

14 – 16 December 2023
We are thrilled to share our participation in the 44th Annual Meeting of the Japan Society of Clinical Pharmacology.
View event